Ovarian neuroendocrine tumors (NET) are rare. We present a 65 year old lady who presented with carcinoid heart disease in the absence of liver metastases who had successful clinical and biochemical resolution following surgical excision of the primary tumor. This case highlights the importance of multidisciplinary team discussion in patients with NET.
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Case details
A previously fit 66 year old female, presented with a 6 month history of shortness of breath and ankle oedema. Echocardiogram revealed severe fixed tricuspid regurgitation, pulmonary valve disease, dilated right heart chambers and preserved left ventricular function. Carcinoid heart disease was suspected and she was referred to our neuroendocrine tumour clinic. She gave a seven year history of facial flushing and diarrhoea. Examination revealed a fixed violaceous facial flush, injected red eyes and evidence of right heart failure. The liver was pulsatile and a large pelvic mass was palpable. Investigations revealed a chromogranin A of 242 nmol/L (0-6) and 5-hydroxyindolacetic acid (5HIAA) at 857 umol/24 hrs (5-37). CT and MRI showed a large solid/cystic 15 cm mass arising from the right ovary, avid on Octreoscan. No lesions were noted in the bowel or liver. Her carcinoid syndrome was controlled with octreotide 50 mg thrice daily subcutaneously with cross over to lanreotide 120 mg deep sc injection every 28 days. Her right heart failure was managed with bumetanide 1 mg daily. After careful review in the Neuroendocrine MDT including gynaecology, cardiology, anaesthetic and HPB surgical review; a joint procedure with the neuroendocrine surgical team and gynaecologist was performed. She underwent an uneventful oophorectomy under octreotide cover (starting at 50mcg/hr the day before surgery) . Histology revealed an ovarian insular carcinoid tumour with lympho vascular space invasion, ENETS grade 1 (KI 67 <1 %). Her 24hr urinary 5HIAA, and chromogranin A, 6 weeks after surgery normalized to 17 umol/24 hrs and 1.8 nmol/L. However she declined cardiac valve surgery.
Abstract Discussion
Ovarian carcinoid tumors are rare neoplasms accounting for only 0.3%-1.0% of all NETS and <0.1% of all ovarian tumors (1).
Occurrence of carcinoid heart disease in ovarian NET is exceedingly rare with only few reported in literature (2).
Vasoactive substances secreted from the carcinoid tumors give rise to the systemic manifestations of carcinoid syndrome as well as carcinoid heart disease. These complicate less than 10% of the rare ovarian NETs (3). Most
NETs have to metastasize to the liver to result in symptoms of carcinoid syndrome; however, primary ovarian carcinoid tumors are unique in this regard because the venous drainage of the ovaries bypasses the portal venous system (4). Ovarian NETs are divided into trabecular, strumal, mucinous and insular types, the latter being the most common and the only one associated with carcinoid syndrome.
Conclusion
Ovarian carcinoid presenting with carcinoid heart disease and syndrome is very rare and needs to be considered in females who present with right heart valve disease. This case highlights the need for MDT discussion in patients with NET. 
